[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100495864":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":34,"centralContacts":39,"locations":50,"responsibleParty":79,"collaborators":44,"id":82,"slug":83,"hasResults":84,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":84,"sex":90,"minAge":91,"maxAge":92,"enrollmentInfo":93,"targetDuration":44,"studyType":96,"phases":97,"briefSummary":100,"conditions":101,"keywords":44,"overallStatus":53,"whyStopped":44,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":112},{"fullName":5,"class":6},"Assiut University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Cis\u002Fatracurium\u002Fsaline placebo","PLACEBO_COMPARATOR","1. The patients will receive 100 ml saline 0.9% at an infusion rate 5 ml\u002Fmin-1) administered 20 min. before induction of anesthesia.\n2. cisatracurium will be administered for intubation at a dose of 0.15 mg\u002Fkg IV and Maintenance at a dose of 0.03 mg\u002Fkg IV",[13],"Drug: Cis-Atracurium",{"label":15,"type":16,"description":17,"interventionNames":18},"Cis-Atracurium\u002FMgSO4","ACTIVE_COMPARATOR","1. The patients will be pretreated with magnesium sulphate infusion (30 mg kg-1, total volume 100 ml, infusion rate 5 ml min-1) 20 min. before induction of anesthesia.\n2. Cis-Atracurium will be administered at 0.1-0.15 mg\u002Fkg IV bolus for intubation and maintenance at a dose of 0.03 mg\u002Fkg iv on fixed intervals.",[19,13],"Drug: MgSO4",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","MgSO4","The patients will be pretreated with magnesium sulphate infusion (30 mg kg-1, total volume 100 ml, infusion rate 5 ml min-1) 20 min. before induction of anesthesia.",[15],[27],"Magnesium Sulfate",{"type":22,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"Cis-Atracurium","Cis-Atracurium will be administered at 0.1-0.15 mg\u002Fkg IV bolus for intubation and maintenance at a dose of 0.03 mg\u002Fkg iv on fixed intervals.",[15,9],[33],"Nimbex",[35],{"name":36,"affiliation":37,"role":38},"Hala Abdel-Ghaffar, MD","Professor of anesthesia and intensive care, faculty of medicine, Assiut university, Assiut, Egypt.","PRINCIPAL_INVESTIGATOR",[40,46],{"name":41,"role":42,"phone":43,"phoneExt":44,"email":45},"Hala S Abdel-Ghaffar, MD","CONTACT","01003812011",null,"hallasaad@yahoo.com",{"name":47,"role":42,"phone":48,"phoneExt":44,"email":49},"Heba S Hassan, Master","01146705556","hebaammar997@gmail.com",[51,69],{"facility":52,"status":53,"city":54,"state":55,"zip":56,"country":57,"countryCode":58,"cosmosGeoPoint":59,"geoPoint":64,"contacts":65},"Pediatric hospital, faculty of medicine, Assiut university","RECRUITING","Asyut","Assiut Governorate","715715","Egypt","EG",{"type":60,"coordinates":61},"Point",[62,63],31.18368,27.18096,{"lat":63,"lon":62},[66],{"name":67,"role":42,"phone":68,"phoneExt":44,"email":45},"Hala S Abdelghaffar, MD","+201003812011",{"facility":70,"status":53,"city":54,"state":55,"zip":56,"country":57,"countryCode":58,"cosmosGeoPoint":71,"geoPoint":73,"contacts":74},"Pediatric hospital",{"type":60,"coordinates":72},[62,63],{"lat":63,"lon":62},[75,77],{"name":41,"role":42,"phone":43,"phoneExt":76,"email":45},"+2 088",{"name":47,"role":42,"phone":48,"phoneExt":44,"email":78},"hebaammar@gmail.com",{"type":38,"investigatorFullName":80,"investigatorTitle":81,"investigatorAffiliation":5,"oldNameTitle":44,"oldOrganization":44},"Hala Saad Abdel-Ghaffar","Principal Investigator","100495864","phase-2-effect-of-magnesium-sulphate-pretreatment-in-pediatric-abdominal-surgery-100495864",false,"NCT05736744","Effect of Magnesium Sulphate Pretreatment in Pediatric Abdominal Surgery","Effect of Magnesium Sulphate Pretreatment on the Onset and Duration of Intense and Deep Neuromuscular Block of Rocuronium Versus Cis-Atracurium in Pediatric Abdominal Surgery","MgSO4\u002FMR","Inclusion Criteria:\n\n1. Age group 2-12 years old\n2. Both genders\n3. Children who will be scheduled to undergo elective laparoscopic surgeries.\n4. Patients with American Society of Anesthesiologist physical status classification of 1 or 2-\n\nExclusion Criteria:\n\n1. Patients who are beyond the selected age group.\n2. Patients on medications that interfered with muscle activity.\n3. Allergy to medications used in this study.\n4. Neuro-muscular diseases.\n5. Renal or hepatic impairment.\n6. Hypermagnesemia (\\>2.5 mmol) or hypomagnesemia (\\\u003C1.7 mmol).\n7. Parental refusal to participate in the study","ALL","2 Years","12 Years",{"count":94,"type":95},58,"ESTIMATED","INTERVENTIONAL",[98,99],"PHASE2","PHASE3","In this study, the investigators will compare the effect of magnesium sulphate pretreatment on the onset and duration of intense and deep neuromuscular Block of rocuronium versus Cis-Atracurium and on the period of no response to nerve stimulation in children undergoing elective open abdominal surgeries.",[102],"Muscle Relaxation","2025-01-17",{"date":105,"type":106},"2025-01-20","ACTUAL",{"date":108,"type":106},"2023-06-20",{"date":110,"type":95},"2025-12-01",{"name":5,"class":6},2]